Belite Bio leverages a proprietary RBP4 (retinol-binding protein 4) intellectual property platform to reduce accumulation of toxins in the eye. The company has advanced Tinlarebant through multiple Phase 3 trials and recently announced positive topline results from its pivotal DRAGON trial in Stargardt disease (December 2025), positioning it for potential regulatory approval within 18-24 months.
Cyborg Score Rationale
Belite Bio demonstrates strong clinical momentum with a positive Phase 3 DRAGON trial result in a rare but commercially attractive orphan indication. The company has orphan drug designation in major markets and a clear path to approval, though execution risk remains inherent to clinical-stage companies.
Top Insights
Phase 3 DRAGON trial of Tinlarebant in Stargardt disease met primary endpoint in December 2025, representing first successful pivotal trial in this indication
Tinlarebant has Orphan Drug Designation in US, Europe, and Japan plus Rare Pediatric Disease designation, supporting accelerated approval pathway
Dual Phase 3 programs: DRAGON/DRAGON II for Stargardt disease and PHOENIX for Geographic Atrophy both actively enrolling/completed